These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 26884284

  • 1. Assessment of OPG, RANKL, bone turnover markers serum levels and BMD after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
    Stuss M, Sewerynek E, Król I, Stępień-Kłos W, Jędrzejczyk S.
    Endokrynol Pol; 2016; 67(2):174-84. PubMed ID: 26884284
    [Abstract] [Full Text] [Related]

  • 2. Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
    Stuss M, Rieske P, Cegłowska A, Stêpień-Kłos W, Liberski PP, Brzeziańska E, Sewerynek E.
    J Clin Endocrinol Metab; 2013 May; 98(5):E1007-11. PubMed ID: 23543663
    [Abstract] [Full Text] [Related]

  • 3. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R, Muñoz-Torres M, García DF, Mezquita-Raya P, García Salcedo JA, de Dios Luna J.
    Menopause; 2010 May; 17(1):140-4. PubMed ID: 19574937
    [Abstract] [Full Text] [Related]

  • 4. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A.
    Horm Metab Res; 2008 Apr; 40(4):281-5. PubMed ID: 18275008
    [Abstract] [Full Text] [Related]

  • 5. Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis.
    Fernández-García D, Muñoz-Torres M, Mezquita-Raya P, de la Higuera M, Alonso G, Reyes-García R, Ochoa AS, Ruiz-Requena ME, Luna JD, Escobar-Jiménez F.
    J Endocrinol Invest; 2008 May; 31(5):416-21. PubMed ID: 18560259
    [Abstract] [Full Text] [Related]

  • 6. Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Pavlidou V, Koukoulis G, Avramidis A.
    Eur J Endocrinol; 2008 Mar; 158(3):411-5. PubMed ID: 18299476
    [Abstract] [Full Text] [Related]

  • 7. Strontium fructose 1,6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway.
    Ma B, Zhang Q, Wu D, Wang YL, Hu YY, Cheng YP, Yang ZD, Zheng YY, Ying HJ.
    Acta Pharmacol Sin; 2012 Apr; 33(4):479-89. PubMed ID: 22426695
    [Abstract] [Full Text] [Related]

  • 8. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
    Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A.
    Osteoporos Int; 2006 Apr; 17(5):693-703. PubMed ID: 16435076
    [Abstract] [Full Text] [Related]

  • 9. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari SM, Ahmadi E, Movahed A, Moradhaseli F, Sanjdideh Z, Obeidi N, Amiri Z.
    Menopause; 2009 Apr; 16(5):950-5. PubMed ID: 19387415
    [Abstract] [Full Text] [Related]

  • 10. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
    D'Amore M, Fanelli M, D'Amore S, Fontana A, Minenna G.
    Panminerva Med; 2006 Dec; 48(4):215-21. PubMed ID: 17215793
    [Abstract] [Full Text] [Related]

  • 11. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K, Perrea D, Doumouchtsis S, Tziamalis M, Poulakou M, Vlachos I, Kostakis A.
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [Abstract] [Full Text] [Related]

  • 12. Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor κB ligand in the diagnosis of osteoporosis.
    Piatek S, Adolf D, Wex T, Halangk W, Klose S, Westphal S, Amthauer H, Winckler S.
    Maturitas; 2013 Apr; 74(4):363-8. PubMed ID: 23391500
    [Abstract] [Full Text] [Related]

  • 13. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C, Gourgiotis D, Kossiva L, Doulgeraki A, Marmarinos A, Galli-Tsinopoulou A, Karavanaki K.
    Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
    [Abstract] [Full Text] [Related]

  • 14. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.
    Martini G, Gennari L, Merlotti D, Salvadori S, Franci MB, Campagna S, Avanzati A, De Paola V, Valleggi F, Nuti R.
    Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395
    [Abstract] [Full Text] [Related]

  • 15. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG, Kim JH, Kim JY, Ku SY, Jee BC, Suh CS, Kim SH, Choi YM.
    Menopause; 2007 Feb; 14(5):913-8. PubMed ID: 17667143
    [Abstract] [Full Text] [Related]

  • 16. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG, Kim JH, Lee DO, Kim H, Kim JY, Suh CS, Kim SH, Choi YM.
    Menopause; 2008 Feb; 15(2):357-62. PubMed ID: 17925661
    [Abstract] [Full Text] [Related]

  • 17. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.
    Dundar U, Kavuncu V, Ciftci IH, Evcik D, Solak O, Cakir T.
    J Bone Miner Metab; 2009 Feb; 27(4):464-70. PubMed ID: 19301089
    [Abstract] [Full Text] [Related]

  • 18. No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.
    Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Ballaouri I, Efstathiadou Z, Kita M, Avramidis A.
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):522-6. PubMed ID: 18625000
    [Abstract] [Full Text] [Related]

  • 19. The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate.
    Middleton ET, Steel SA, Aye M, Doherty SM.
    J Bone Miner Res; 2010 Mar; 25(3):455-62. PubMed ID: 20201000
    [Abstract] [Full Text] [Related]

  • 20. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
    Gifre L, Ruiz-Gaspà S, Carrasco JL, Portell E, Vidal J, Muxi A, Monegal A, Guañabens N, Peris P.
    Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.